If a woman is 55 years old or older and experiences postmenopausal bleeding (which occurs after 12 months of no menstruation), she should be referred for further evaluation within 2 weeks using the suspected cancer pathway to rule out endometrial cancer.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

If a patient with stress incontinence does not respond to pelvic floor muscle exercises and declines surgical intervention, duloxetine may be used. Antimuscarinics are the first-line treatment for urge incontinence in patients who do not respond to bladder training, with oxybutynin (immediate-release), tolterodine (immediate-release), or darifenacin (once daily preparation) being recommended by NICE. Mirabegron, a beta-3 agonist, is used when antimuscarinics are contraindicated or when there are concerns about their side effects, particularly in frail elderly women. Desmopressin is not a treatment for stress incontinence, but it may be considered off-label for patients with troublesome nocturia, except for women aged 65 years or over with cardiovascular disease or hypertension.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

When managing a miscarriage, medical treatment typically involves administering vaginal misoprostol alone. According to the NICE miscarriage Clinical Knowledge Summary, medical management is recommended if expectant management is not suitable or if a woman continues to experience symptoms after 14 days of expectant management. Misoprostol can be given orally or vaginally. If products of conception are not expelled after medical treatment or if symptoms persist after 14 days of expectant management, manual vacuum aspiration or surgical management may be considered. However, hospitalization and observation are not usually necessary unless the patient is experiencing hemodynamic instability. In most cases, women can take misoprostol and complete the miscarriage at home. Oral methotrexate is used for medical management of ectopic pregnancy.

Management Options for Miscarriage

Miscarriage can be a difficult and emotional experience for women. In the 2019 NICE guidelines, three types of management for miscarriage were discussed: expectant, medical, and surgical. Expectant management involves waiting for a spontaneous miscarriage and is considered the first-line option. However, if it is unsuccessful, medical or surgical management may be offered.

Medical management involves using tablets to expedite the miscarriage. Vaginal misoprostol, a prostaglandin analogue, is used to cause strong myometrial contractions leading to the expulsion of tissue. It is important to advise patients to contact their doctor if bleeding does not start within 24 hours. Antiemetics and pain relief should also be given.

Surgical management involves undergoing a surgical procedure under local or general anaesthetic. The two main options are vacuum aspiration (suction curettage) or surgical management in theatre. Vacuum aspiration is done under local anaesthetic as an outpatient, while surgical management is done in theatre under general anaesthetic. This was previously referred to as ‘Evacuation of retained products of conception’.

It is important to note that some situations are better managed with medical or surgical management, such as an increased risk of haemorrhage, being in the late first trimester, having coagulopathies or being unable to have a blood transfusion, previous adverse and/or traumatic experience associated with pregnancy, evidence of infection, and more. Ultimately, the management option chosen should be based on the individual patient’s needs and preferences.

How the Copper IUD Affects Different Parts of Sperm

The copper IUD is a popular form of birth control that works by preventing fertilization. It does this by affecting different parts of the sperm. The Golgi apparatus, which contributes to the acrosome of the sperm, is inhibited by the IUD, preventing capacitation. The mitochondria, which form the middle piece of the sperm, are not affected. The nucleus is also unaffected. Sperm do not have cell walls, so this is not a factor. Finally, the centrioles contribute to the flagellum of the sperm, but the copper IUD does not target this part of the sperm. Understanding how the copper IUD affects different parts of the sperm can help individuals make informed decisions about their birth control options.

According to Good Medical Practice (2013), if you have a conscientious objection to a particular procedure, it is your responsibility to inform your patients and explain their right to see another doctor. You must provide them with sufficient information to exercise this right without expressing any disapproval of their lifestyle, choices, or beliefs. It is important to ensure that your personal views do not unfairly discriminate against patients or colleagues and do not affect the treatment you provide or arrange.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, except in emergencies where only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise.

The method used to terminate a pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone (an anti-progesterone) is administered, followed by prostaglandins 48 hours later to stimulate uterine contractions. For pregnancies less than 13 weeks, surgical dilation and suction of uterine contents is used. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion (inducing ‘mini-labour’) is used.

The 1967 Abortion Act outlines the circumstances under which a person shall not be guilty of an offence under the law relating to abortion. These include if two registered medical practitioners are of the opinion, formed in good faith, that the pregnancy has not exceeded its 24th week and that the continuance of the pregnancy would involve risk, greater than if the pregnancy were terminated, of injury to the physical or mental health of the pregnant woman or any existing children of her family. The limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

Although clinical features such as infrequent or absent ovulation and hyperandrogenism can suggest PCOS, NICE CKS recommends using specific diagnostic criteria. To diagnose PCOS, at least 2 out of 3 of the following criteria should be present: infrequent or no ovulation, signs of hyperandrogenism or elevated testosterone levels, and polycystic ovaries or increased ovarian volume on ultrasonography. It is important to note that a high BMI is not part of the diagnostic criteria, but signs of insulin resistance such as acanthosis nigricans may aid in diagnosis.

Polycystic ovary syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is believed to involve both high levels of luteinizing hormone and hyperinsulinemia, with some overlap with the metabolic syndrome. PCOS is characterized by a range of symptoms, including subfertility and infertility, menstrual disturbances such as oligomenorrhea and amenorrhea, hirsutism, acne, obesity, and acanthosis nigricans.

To diagnose PCOS, a range of investigations may be performed, including pelvic ultrasound to detect multiple cysts on the ovaries. Other useful baseline investigations include FSH, LH, prolactin, TSH, testosterone, and sex hormone-binding globulin (SHBG). While a raised LH:FSH ratio was once considered a classical feature of PCOS, it is no longer thought to be useful in diagnosis. Testosterone may be normal or mildly elevated, but if markedly raised, other causes should be considered. SHBG is typically normal to low in women with PCOS, and impaired glucose tolerance should also be checked.

To formally diagnose PCOS, other conditions must first be excluded. The Rotterdam criteria state that a diagnosis of PCOS can be made if at least two of the following three criteria are present: infrequent or no ovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound scan. Polycystic ovaries are defined as the presence of at least 12 follicles measuring 2-9 mm in diameter in one or both ovaries, and/or an increased ovarian volume of over 10 cm³.

The patient should not restart the COCP within the first 21 days after giving birth due to the increased risk of venous thromboembolism. However, since the patient is not breastfeeding and has no additional risk factors for thromboembolic disease, she can safely restart the pill at 3 weeks postpartum. Restarting at any other time before the 21-day mark is not recommended.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

For a patient who has had unprotected intercourse within the last 72 hours and is seeking the most effective form of emergency contraception, the recommended course of action is to arrange for a copper coil (IUD) insertion. This method is effective for up to five days (120 hours) after intercourse, whether or not ovulation has occurred, and works by preventing fertilization or implantation. If there are concerns about sexually transmitted infections, antibiotics can be given at the same time. It is incorrect to advise the patient that she has missed the window for emergency contraception, as both the copper coil and ulipristal acetate are licensed for use up to five days after intercourse, while levonorgestrel emergency contraception can be taken up to 72 hours after. Prescribing levonorgestrel emergency contraception would not be the best option in this case, as its efficacy decreases with time and it is minimally effective if ovulation has already occurred. Similarly, ulipristal acetate may be less effective if ovulation has already occurred, so a copper coil insertion would be a more appropriate choice.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Investigations for Endometriosis: Methods and Recommendations

Endometriosis is a common cause of dysmenorrhoea, and various investigations are available to diagnose it. The National Institute for Health and Care Excellence (NICE) recommends transvaginal ultrasound (TVUS) as the first-line investigation for suspected endometriosis. TVUS can detect ovarian endometriomas or involvement of structures like the uterosacral ligament. However, a definitive diagnosis of endometriosis can only be made by laparoscopy, which is a minimally invasive procedure. Laparotomy with biopsy is rarely used due to longer recovery times and increased risk of complications. Magnetic resonance imaging (MRI) pelvis is not recommended as the first-line investigation, but it may be considered if there is suspicion of deep endometriosis affecting other organs like the bowel or bladder. Transabdominal ultrasound is only considered if TVUS cannot be done. In conclusion, TVUS and laparoscopy are the preferred methods for investigating endometriosis, with other investigations being considered only in specific situations.

Women can begin using hormonal contraception right away after taking levonorgestrel (Levonelle) for emergency contraception. However, if ulipristal acetate was used instead, it is recommended to wait for 5 days or use barrier methods before resuming hormonal contraception.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

In the NHS cervical screening programme, cervical cancer screening involves testing for high-risk HPV (hrHPV) first. If the initial test results in an inadequate sample, it should be repeated after 3 months. If the second test also returns as inadequate, then colposcopy should be performed. This is because without obtaining hr HPV status or performing cytology, the risk of cervical cancer cannot be assessed. It would be unsafe to return the patient to normal recall as this could result in a delayed diagnosis of cervical cancer. Repeating the test after 3, 6 or 12 months is also not recommended as it may lead to a missed diagnosis.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hr HPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Management Options for Endometriosis-Related Pain: A Guide for Healthcare Professionals

Endometriosis is a condition where endometrial tissue grows outside the uterus, causing pain and discomfort. Hormonal contraception is an effective treatment option for women who do not wish to conceive. The combined oral contraceptive pill suppresses ovarian function and limits the effect of estrogen on endometrial tissue. progesterone-containing contraceptives cause atrophy of the endometrial tissue. A trial of three months is recommended before reassessment.

Hysterectomy is indicated for adenomyosis or heavy menstrual bleeding that has not resolved with other treatments. A hysteroscopy is not necessary for a newly diagnosed young patient. A trial of ibuprofen or combination therapy is the first step in pain management, but NSAIDs are contraindicated for asthmatic patients who have already tried paracetamol.

Further laparoscopy for excision and/or ablation of endometriotic deposits is indicated if there is further disease. However, if all visible deposits were removed during diagnostic laparoscopy, a further laparoscopy is not necessary at present.

Ovarian cystectomy is recommended for women with endometriotic cysts who are concerned about fertility. Laparoscopic removal of the cyst wall can improve the chances of spontaneous pregnancy and reduce the risk of recurrence of endometriomas. These guidelines are based on NICE recommendations.

postmenopausal Bleeding: Common Causes and Investigations

postmenopausal bleeding can be caused by various factors, including atrophic vaginitis, endometrial atrophy, cervical or endometrial polyps, and endometrial hyperplasia/cancer. Among these causes, endometrial cancer is the most likely. Therefore, investigation for patients with postmenopausal bleeding is typically done in a specialist clinic, with transvaginal ultrasound, hysteroscopy, and biopsy.

However, submucosal fibroids become quiescent following menopause and usually calcify, and there is no evidence of increased risk of endometrial cancer in women with fibroids. On the other hand, ovarian cancer rarely, if ever, presents with postmenopausal bleeding. Cervical ectropion is a condition of young women, and vaginal cancer is very rare and usually presents with vaginal discharge.

In summary, postmenopausal bleeding should be investigated thoroughly to rule out any underlying serious conditions, such as endometrial cancer.

Ovulation induction can lead to ovarian hyperstimulation syndrome (OHSS) as a potential side effect. The symptoms of OHSS often involve gastrointestinal discomfort such as bloating, abdominal pain, nausea, vomiting, and diarrhea. Additionally, patients may experience shortness of breath, fever, peripheral edema, and oliguria. OHSS can range in severity from mild to life-threatening, with complications such as dehydration, thromboembolism, acute kidney injury (AKI), and pulmonary edema. Severe OHSS typically has a delayed onset compared to milder cases. In the given scenario, the patient received a GnRH agonist injection within the past week, indicating that her symptoms may be less severe.

Ovulation induction is often required for couples who have difficulty conceiving naturally due to ovulation disorders. Normal ovulation requires a balance of hormones and feedback loops between the hypothalamus, pituitary gland, and ovaries. There are three main categories of anovulation: hypogonadotropic hypogonadal anovulation, normogonadotropic normoestrogenic anovulation, and hypergonadotropic hypoestrogenic anovulation. The goal of ovulation induction is to induce mono-follicular development and subsequent ovulation to lead to a singleton pregnancy. Forms of ovulation induction include exercise and weight loss, letrozole, clomiphene citrate, and gonadotropin therapy. Ovarian hyperstimulation syndrome is a potential side effect of ovulation induction and can be life-threatening if not managed promptly.

When a woman with risk factors for infertility, such as damage to the contralateral tube, has an ectopic pregnancy requiring surgical management, it is recommended to consider salpingostomy instead of salpingectomy. In this case, the woman has a left-sided ectopic pregnancy and a damaged right tube, making salpingostomy a more appropriate option to preserve her fertility. Methotrexate is not suitable for this case due to the severity of pain, and monitoring for 48 hours is not appropriate either. Expectant management is only recommended for small, asymptomatic ectopic pregnancies without cardiac activity.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

For non-pregnant women with vaginal thrush, the recommended first-line treatment is a single-dose of oral fluconazole. This is based on NICE guidelines for the diagnosis of vaginal candidiasis. The use of clotrimazole intravaginal pessary is only recommended if the patient is unable to take oral treatment due to safety concerns. Oral nystatin is not appropriate for this condition as it is used for oral candidiasis. While topical clotrimazole can be used to treat vaginal candidiasis, it is not the preferred first-line treatment and should only be used if fluconazole is not effective or contraindicated.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

Causes and Precipitants of Urge Incontinence: A Brief Overview

Urge incontinence, characterized by involuntary leakage of urine associated with or following urgency, is a common condition in women. It is caused by overactivity of the detrusor muscle in the bladder wall, leading to irregular contractions during the filling phase and subsequent leakage of urine. While there are many causes and precipitants of urge incontinence, it is often difficult to identify a single factor in the presence of multiple contributing factors.

Some of the common causes of urge incontinence include poorly controlled diabetes, excess caffeine and alcohol intake, neurological dysfunction, urinary infection or faecal impaction, and adverse medication effects. In the case of a patient presenting with a short history of symptoms, urinary tract infection is the most likely cause, and prompt treatment is necessary to prevent complications.

It is important to rule out developing cauda equina, a medical emergency that can lead to paralysis, in patients presenting with short-term urinary incontinence. Normal anal tone and perineal sensation can help exclude this condition.

Excess alcohol and caffeine intake can precipitate symptoms of urge incontinence by inducing diuresis, causing frequency and polyuria. Chronic constipation, particularly in patients with diverticular disease, can also compress the bladder and lead to urge incontinence symptoms. Systemic illnesses such as diabetes mellitus can cause glycosuria and polyuria, leading to bladder irritation and detrusor instability. Finally, oestrogen deficiency associated with postmenopausal status can cause vaginitis and urethritis, both of which can precipitate urge incontinence symptoms.

In conclusion, urge incontinence is a complex condition with multiple contributing factors. Identifying and addressing these factors can help manage symptoms and improve quality of life for affected patients.

To diagnose PCOS, at least two out of three features must be present: oligomenorrhoea, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound. In this case, the patient has oligomenorrhoea and clinical signs of hyperandrogenism, making a clinical diagnosis of PCOS likely. However, NICE guidelines recommend ruling out other potential causes of menstrual disturbance before confirming the diagnosis. BMI measurement is not necessary for diagnosis, although obesity is a common feature of PCOS. Testing for free or total testosterone levels is also not essential if clinical signs of hyperandrogenism are present.

Polycystic ovary syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is believed to involve both high levels of luteinizing hormone and hyperinsulinemia, with some overlap with the metabolic syndrome. PCOS is characterized by a range of symptoms, including subfertility and infertility, menstrual disturbances such as oligomenorrhea and amenorrhea, hirsutism, acne, obesity, and acanthosis nigricans.

To diagnose PCOS, a range of investigations may be performed, including pelvic ultrasound to detect multiple cysts on the ovaries. Other useful baseline investigations include FSH, LH, prolactin, TSH, testosterone, and sex hormone-binding globulin (SHBG). While a raised LH:FSH ratio was once considered a classical feature of PCOS, it is no longer thought to be useful in diagnosis. Testosterone may be normal or mildly elevated, but if markedly raised, other causes should be considered. SHBG is typically normal to low in women with PCOS, and impaired glucose tolerance should also be checked.

To formally diagnose PCOS, other conditions must first be excluded. The Rotterdam criteria state that a diagnosis of PCOS can be made if at least two of the following three criteria are present: infrequent or no ovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound scan. Polycystic ovaries are defined as the presence of at least 12 follicles measuring 2-9 mm in diameter in one or both ovaries, and/or an increased ovarian volume of over 10 cm³.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

Ectopic Pregnancy: Sites and Symptoms

Ectopic pregnancy is a condition where the fertilized egg implants outside the uterine cavity. The most common site for ectopic implantation is the Fallopian tube, particularly the ampullary region, accounting for 97% of cases. Symptoms include 4-8 weeks of amenorrhea, abdominal pain, vaginal bleeding, and signs of shock associated with rupture. Shoulder tip pain may also occur due to irritation of the phrenic nerve. Diagnosis is made through measurement of β-human chorionic gonadotrophin and ultrasound scan of the abdomen, with laparoscopic investigation as the definitive method. Treatment involves removal of the pregnancy and often the affected tube via laparoscopy or laparotomy.

Other sites for ectopic pregnancy include the peritoneum or abdominal cavity, which accounts for 1.4% of cases and may proceed to term. Cervical pregnancy is rare, accounting for less than 1% of cases. Ovarian pregnancy occurs in 1 in 7000 pregnancies and accounts for 0.5-3% of all ectopic pregnancies. The broad ligament is an uncommon site for ectopic pregnancies due to its poor vascularity.

Diagnostic Tests and Imaging for Lower Abdominal Pain in Women

Lower abdominal pain in women can have various causes, including appendicitis, urinary tract infection, ovarian or tubal pathology, pelvic inflammatory disease, ruptured ectopic pregnancy, mesenteric adenitis, and other less common pathologies. To determine the cause of the pain, several diagnostic tests and imaging techniques can be used.

Beta human choriogonadotropin (β-hCG) test is essential for every woman of reproductive age admitted with lower abdominal pain. This test helps determine the pregnancy status, which can guide further investigations. An abdominal/pelvic ultrasound can detect acute ovarian and other gynecological pathology. It is also useful in assessing biliary pathology and involvement in pancreatitis. However, it is not very sensitive in detecting appendicitis.

If the diagnosis is uncertain, admitting the patient for observation and review in 12 hours can help determine if any other signs or symptoms develop or change. A CT scan would be inappropriate without checking the patient’s pregnancy status, as it could be harmful to the fetus. However, it can be useful in delineating acute intestinal pathology such as inflammatory bowel disease, bowel obstruction, and renal calculi.

Finally, an erect chest X-ray can help determine if there is bowel perforation by assessing for air under the diaphragm. This investigation is critical in the presence of a peritonitic abdomen.

In conclusion, a combination of diagnostic tests and imaging techniques can help determine the cause of lower abdominal pain in women and guide appropriate treatment.

Patients with stress incontinence who do not respond to pelvic floor muscle exercises and decline surgical intervention may be prescribed duloxetine, a serotonin-norepinephrine re-uptake inhibitor. This drug increases sphincter tone during the filling phase of urinary bladder function. However, before starting drug therapy, patients should try pelvic floor exercises and consider surgical intervention. Oxybutynin, an anticholinergic drug, is used to treat urge incontinence or symptoms of detrusor overactivity, but it is not recommended for frail, older women at risk of health deterioration. Desmopressin is the preferred drug treatment for children with nocturnal enuresis and may also be used for women with nocturia. Mirabegron is prescribed for patients with urge incontinence who cannot tolerate antimuscarinic/anticholinergic drugs. It is a beta-3 adrenergic agonist that relaxes the bladder.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

The menopause is diagnosed retrospectively and occurs 12 months after the last menstrual period. Women who experience menopause before the age of 50 need contraception for at least 2 years after their last menstrual period, while those over 50 require only 1 year of contraception. Therefore, it would be incorrect to assume that this woman does not need contraception because she is protected. Prescribing the COCP for only 12 months would also be inappropriate, especially since she is a smoker over the age of 35. Hormone replacement therapy should not be used as a sole form of contraception, and barrier methods are less effective than other types of contraception. The most appropriate option is the IUS, which can be used for 7 years (off-licence) or 2 years after her last menstrual period and will take her through menopause. This information is based on the FSRH’s guidelines on contraception for women aged over 40 (July 2010).

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. On average, women in the UK experience menopause at the age of 51. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

The Levonorgestrel intrauterine system is the appropriate choice for this patient as it is a long-acting contraceptive that can also help prevent heavy menstrual bleeding. It can be inserted immediately as the patient is within 48 hours of childbirth. The Copper intrauterine device should be avoided in those with a history of heavy menstrual bleeding. The lactational amenorrhoea method is only effective for up to 6 months post-partum, and progesterone injections must be repeated every 10-12 weeks, making them unsuitable for this patient’s desire for a long-term contraceptive.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

When a cervical cancer screening smear is inadequate, the recommended course of action is to repeat the smear within 3 months. It is not necessary to consider any previous inadequate smears from a decade ago. Therefore, repeating the smear in 1 month or 3 years is not appropriate. Referral for colposcopy or gynaecology is also not necessary at this stage, as it should only be considered if the second smear in 3 months’ time is also inadequate.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

A woman’s ovulation usually occurs on day 14 of her 28-day menstrual cycle. After ovulation, hormonal changes occur.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

The correct course of action for a patient who had a positive high-risk human papillomavirus (hrHPV) but negative cytology result in their initial smear and a negative hrHPV result in their subsequent 12-month repeat smear is to return to routine recall. This means that the patient should have their next smear in 5 years, as they are in the appropriate age group for this interval. Referring the patient for colposcopy is not necessary in this case, as the cytology result was negative. Repeating the smear in 3 months is also not necessary, as this is only done for inadequate samples. If the hrHPV result is positive again in a further 12-month repeat, then repeating the smear in another 12 months would be appropriate. However, if the hrHPV result is negative in the second repeat, the patient can be returned to routine recall. For younger patients, the appropriate interval for routine recall is 3 years.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

When a teenage girl experiences regular painful cycles but has not yet started menstruating, an imperforate hymen is a likely cause. This condition blocks the flow of menstrual blood, leading to primary amenorrhoea while allowing for normal development of secondary sexual characteristics like pubic hair and breast growth. The accumulation of menstrual blood in the vagina can cause discomfort and bloating due to pressure. Other potential causes of amenorrhoea include chemotherapy during childhood, Turner’s syndrome, and polycystic ovary syndrome, which can all interfere with the production of estrogen and the development of secondary sexual characteristics.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls without secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

The menopause is a natural process that occurs when a woman’s menstrual periods stop due to decreased production of oestradiol and progesterone. While menopause can cause symptoms such as hot flashes, mood changes, and reduced libido, treatment with hormone replacement therapy (HRT) is not necessary and should be based on individual circumstances and patient choice. However, if HRT is used, it is important to note that oestrogen-only therapy can increase the risk of endometrial cancer and should only be given to women without a uterus. This is because oestrogen promotes endometrial growth, which can lead to oncogenesis. Adding progesterone to HRT can prevent this risk. Testosterone may also be used to address libido issues, but it should be prescribed under specialist guidance and can cause virilising side-effects. Selective serotonin reuptake inhibitors (SSRIs) such as venlafaxine can be an alternative to HRT and are effective at managing symptoms without increasing the risk of endometrial cancer. However, SSRIs can cause side-effects such as gastrointestinal disturbances, reduced libido, and potentially life-threatening serotonin syndrome.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.